Zacks Research Issues Pessimistic Forecast for SRPT Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a report released on Monday, January 6th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings of $1.90 per share for the quarter, down from their previous forecast of $1.98. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.16 per share. Zacks Research also issued estimates for Sarepta Therapeutics' Q2 2025 earnings at $2.63 EPS, Q3 2025 earnings at $2.60 EPS, Q4 2025 earnings at $2.83 EPS, FY2025 earnings at $9.95 EPS, Q1 2026 earnings at $3.04 EPS, Q2 2026 earnings at $3.56 EPS, Q3 2026 earnings at $3.53 EPS, Q4 2026 earnings at $3.53 EPS and FY2026 earnings at $13.66 EPS.

Other equities analysts have also issued research reports about the company. Raymond James reiterated an "outperform" rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. StockNews.com cut shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. Robert W. Baird lowered their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research note on Thursday, November 7th. Finally, Jefferies Financial Group began coverage on Sarepta Therapeutics in a report on Monday, October 21st. They set a "buy" rating and a $165.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $178.71.

Sarepta Therapeutics Stock Up 1.4 %

Shares of SRPT traded up $1.78 during trading hours on Thursday, hitting $126.27. The company had a trading volume of 727,210 shares, compared to its average volume of 591,882. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $12.06 billion, a PE ratio of 101.02 and a beta of 0.77. Sarepta Therapeutics has a one year low of $102.15 and a one year high of $173.25. The company's fifty day moving average price is $122.11 and its two-hundred day moving average price is $131.33.

Insiders Place Their Bets

In other news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company's stock, valued at $738,234. This represents a 21.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Institutional Trading of Sarepta Therapeutics

Institutional investors have recently bought and sold shares of the business. Nkcfo LLC purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at approximately $43,000. Sunbelt Securities Inc. raised its position in Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 232 shares during the period. Huntington National Bank lifted its holdings in Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. UMB Bank n.a. grew its position in shares of Sarepta Therapeutics by 105.9% in the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 197 shares during the period. Finally, Values First Advisors Inc. purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth about $59,000. 86.68% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.